Samsung C&T and Samsung Electronics have announced a significant joint investment of $110 million in GRAIL, Inc., a healthcare company focused on early cancer detection. This agreement, still subject to closing and preliminary conditions, marks an important advance in the collaboration between these entities to commercialize the Galleri test, an innovative screening designed for the early detection of more than 50 types of cancer in key markets in Asia.
Samsung C&T will lead the marketing of Galleri in South Korea, with plans to expand into Japan and Singapore. This test, which relies on a simple blood draw, aims to detect cancer signals before symptoms appear. Initially, testing will be conducted at GRAIL’s clinical laboratory located in Research Triangle Park, North Carolina.
Jaywoo Kim, executive vice president of the life sciences business at Samsung C&T, emphasized that this collaboration is not limited to an economic investment, but represents a strategic alliance that will allow Samsung to strengthen its presence in cancer detection. At the same time, Samsung Electronics and GRAIL are in discussions to explore potential collaborations in areas such as the integration of health data platforms and genomic clinical research, which could enhance the capabilities of both entities and improve patient care.
Hon Pak, senior vice president and leader of Samsung Electronics’ digital health team, emphasized that this investment is part of a broader vision to contribute to the health of billions of people. According to Pak, the collaboration with GRAIL will enable the integration of artificial intelligence technologies and digital platforms with clinical data.
The signing of the definitive agreement is expected in early 2026, with business operations anticipated to begin shortly thereafter. GRAIL will act as the exclusive distributor of the Galleri test in South Korea, and potentially in Japan and Singapore, once all necessary requirements are met. This investment also needs to be approved by regulatory authorities, as well as meet other customary conditions.
This move underscores Samsung’s commitment to expanding its biotechnology portfolio and its focus on improving quality of life through innovations in early cancer detection.
Source: MiMub in Spanish
